Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

NCT02566772 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG: TAS3681

Sponsor

Taiho Oncology, Inc.